Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hope for a broken heart?

Patrick Most1, Carmen Eicher, Mirko Völkers

  • 1Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. patrick_most@med.uni-heidelberg.de

Trends in Biotechnology
|September 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Darbepoetin inhibits proliferation of hepatic cancer cells in the presence of TGF-β.

Archives of toxicology·2013
Same author

Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.

Oncology reports·2012
Same author

Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.

Pediatric surgery international·2012
Same author

Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?

Clinical research in cardiology : official journal of the German Cardiac Society·2012
Same author

Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A.

Biochemical and biophysical research communications·2012
Same author

Atrioventricular delay programming in cardiac resynchronization therapy devices: fixed or adaptive? A randomized monocenter trial.

Journal of electrocardiology·2012

Targeted gene transfer to inhibit beta-adrenergic receptor kinase 1 (betaARK1) improved heart function in failing human hearts. This approach shows promise for future heart failure therapies by restoring beta-adrenergic responsiveness.

Area of Science:

  • Cardiology
  • Molecular Medicine
  • Gene Therapy

Background:

  • Heart failure impacts millions globally, marked by reduced cardiac function and impaired beta-adrenergic stimulation.
  • Existing therapies face limitations in restoring contractile function in advanced heart failure.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting beta-adrenergic receptor kinase 1 (betaARK1) in failing human myocardium.
  • To assess the efficacy of gene transfer for targeted betaARK1 inhibition.

Main Methods:

  • Utilized gene transfer techniques to deliver a therapeutic agent targeting betaARK1.
  • Evaluated the impact of betaARK1 inhibition on contractile function and beta-adrenergic responsiveness in human heart failure models.

Related Experiment Videos

Main Results:

  • Demonstrated successful inhibition of betaARK1 in failing human myocardium via gene transfer.
  • Observed significant improvements in cardiac contractile function.
  • Restored responsiveness to beta-adrenergic stimulation in the treated myocardium.

Conclusions:

  • Gene transfer-mediated betaARK1 inhibition is a viable strategy to enhance cardiac function in heart failure.
  • This proof-of-concept study supports betaARK1 inhibition as a promising therapeutic avenue for heart failure patients.
  • Further research into this gene therapy approach could lead to novel treatments for cardiac dysfunction.